Safinamide in Parkinson’s disease: No hint of added benefit

Regarding Safinamide in Parkinson’s disease, reviewers state that since since relevant study data were not considered, analyses in the dossier were incomplete regarding serious side effects in the comparator therapy, long-term data and other aspects.

Source:: Science Daily

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *